HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Monograph Stakeholders Seek Confidentiality Assurances Ahead Of OMOR Meetings With FDA

Executive Summary

Judging by January draft guidance from the US FDA, the agency may feel compelled to make public any information a party submits in the context of a meeting to discuss data needs for an OTC monograph change. And special sunscreen considerations included in the CARES Act, which overhauled the FDA's OTC drug review program, aren't mentioned in the guidance, trade groups say.

You may also be interested in...



OTC Monograph User Fees Grow In FDA FY2023 Budget Request And In Industry's Thinking

Stakeholders didn’t indicate extensive familiarity with OTC monograph user fees during online workshop. Biden administration’s FDA FY2023 budget request includes $5m increase to $30.36m in facility registration fees required from all firms manufacturing OTC monograph drugs available in US.

'Milestone' Discussions With US FDA On OTC Monograph Proposals Limited To One Meeting

Recent draft guidance on scheduling and conducting meetings with FDA supported by OTC monograph user fees largely tracks with agency’s guidance for meetings supported by other user fee programs, such as PDUFA.

US House Appropriators Seek Data On Fragrance Allergens In Cosmetics, ‘Balance’ In Sunscreen Regs

The House Appropriations Committee asks the US Food and Drug Administration to provide a report to Congress in two years on the resources it would need to develop a database for fragrance allergens used in cosmetics. The committee’s report accompanying FY2023 FDA funding legislation also touches on OTC sunscreen regulation, PFAS in cosmetics, skin-lightening ingredients, and more.

Topics

Latest News
UsernamePublicRestriction

Register

RS152465

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel